Deoxyribonuclease 1 like 3 (DNASE1L3) facilitates double-strand deoxyribonucleic acid (dsDNA) breaks generation and activates AIM2 pathway during sorafenib treatment to trigger PANoptosis and decrease the hepatocellular carcinoma cell survival [86]. The gene discussed is DNASE1L3; the disease is hepatocellular carcinoma.